Friday’s verdict comes at a time when many physicians are rethinking the long-term use of Fosamax and other osteoporosis drugs known as oral bisphosphonates. Last month, the Food and Drug Administration issued a public advisory saying the drugs had been linked with — although not definitively as the cause of — rare thigh fractures. The agency will now require the labels of oral bisphosphonates to state that the optimum duration of taking the drugs is not known
via nytimes.com
